Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Administrative Sanction on MTPC Too Harsh: Mr Gohara
April 26, 2010
- Korosho Asks 4 Companies to Develop IPV
April 26, 2010
- Toho HD to Merge Asucome in October
April 26, 2010
- Carna Biosciences' R&D Project to Be Funded by NIBIO
April 26, 2010
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
- BI Launches Global Venture Fund
April 26, 2010
- Isentress Recommended for Lack of Effects on Lipids: Dr Hanabusa
April 26, 2010
- Biomedical Cluster Kansai Changes Its Operation Systems
April 26, 2010
- Only 12.6% of the Elderly Aware of Pneumococcal Vaccines
April 26, 2010
- 14 New Products Approved by Korosho
April 26, 2010
- 3,787 Pass National Exam for Pharmacists with Pass Rate of 56.35%
April 26, 2010
- FPMAJ to Determine Measures to Enhance Ethical Compliance
April 26, 2010
- Bayer to Increase Sales of New Drugs to 50% of Total Sales
April 26, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…